Wuhan Desheng Biochemical Technology Co., Ltd

In today's rapidly developing global medical testing technology, chemiluminescence reagents, as "precise probes" in the field of in vitro diagnostics (IVD), are writing a differentiated market landscape with changes in economic and medical needs in different regions. From the vibrant vitality of emerging markets in Asia to the stable landscape of mature markets in Europe and America, the competition and opportunities in this blue ocean reflect profound changes in the global healthcare industry. 1, Asia: Accelerating the Start of Growth Engines On this vibrant land of Asia, the chemiluminescence reagent market is reshaping the industry landscape at an astonishing speed. When the skyscrapers in Lujiazui, Shanghai and the technology park in Bangalore, India shine together, it is the awakening of health awareness among hundreds of millions of people. The wave of urbanization has not only changed the skyline, but also promoted the upgrading of primary healthcare facilities - from tertiary hospitals to community clinics, the popularization of detection equipment has enabled chemiluminescence technology to reach a wider range of people. China and India, as dual drivers of regional development, demonstrate a unique development logic. In the medical device industry park in Shenzhen, the chemiluminescence detection system developed by local enterprises has been able to achieve "same day sampling, same day results", and this efficiency innovation is radiating from big cities to county-level medical centers. The graded diagnosis and treatment policy implemented by the government is like a conveyor belt, delivering advanced testing technology to every corner that needs it. The thriving private healthcare system in India has created a unique development model by combining the introduction of international equipment with localized reagents. It is worth noting that innovative forces are rising on this land. A biotechnology company located in Suzhou has reduced testing costs by 30% by improving reagent formulations, enabling remote health centers to conduct thyroid function screening. This down-to-earth technological innovation is a vivid footnote to the vitality of the Asian market. 2, Europe and America: Maintaining Integrity in Mature Markets and Emerging Innovation The European and American markets spanning the Atlantic exhibit different developmental rhythms. At the medical exhibition in Munich, Germany, the century old brand's chemiluminescence instrument still occupies the C position, but the most discussed topic in front of the booth is no longer simply parameter competition, but how to extend the equipment's life cycle through intelligent transformation. This transformation reveals the survival philosophy of mature markets: mining service value in stock competition. The strict healthcare regulatory system in Europe is like a double-edged sword. It not only ensures the stability of testing quality, but also makes the admission of new products like crossing layers of checkpoints. But wise practitioners have found a way to break through - an Italian company has combined a chemiluminescence platform with blockchain technology to create a fully traceable detection system that meets regulatory requirements and creates new service premiums. The arena of the North American market is filled with "songs of ice and fire". In the biotechnology cluster area of Boston, startups are attempting to disrupt traditional testing models with miniaturized devices, while established giants are consolidating their moats by acquiring innovative reagent companies. This continuous technological iteration ensures that even in the context of slowing market growth, the spark of innovation continues to thrive. 3, Future vision: Technology accessibility and value reconstruction From a global perspective, the regional differences in the chemiluminescence reagent market are essentially a mirror reflection of the uneven distribution of medical resources. While the Asian market is still addressing the question of 'whether or not', the European and American markets are already exploring higher pursuits of 'whether or not'. This development gap precisely provides space for technology transfer and model innovation. It is worth looking forward to that the digital wave is blurring geographical boundaries. A cloud based quality control system developed by a Singaporean company can provide real-time data support for both community hospitals in Bangkok and private clinics in Chicago. This technology sharing that transcends geographical limitations may reshape the rules of competition in the future. Under the wave of silver hair in an aging society, the demand for testing has grown beyond geographical limitations. The Alzheimer's disease early screening kit developed in Japan has been widely used in elderly physical examinations in the Yangtze River Delta region after localization and improvement by Chinese companies; The tumor marker detection scheme developed by Germany has also been produced in India through technology authorization. This global collaborative innovation ecosystem is writing a new narrative for industry development.

Industry opportunities under the global economic development trend Against the backdrop of a "K-shaped recovery" in the global economy, the in vitro diagnostic industry is facing opportunities for differentiated development. In 2023, the global medical device market size will exceed $580 billion, with the in vitro diagnostic sector continuing to increase to 13.2%. As the largest individual market, the export value of IVD products in the United States increased by 8.7% year-on-year, while the European Union's market concentration has significantly increased after the implementation of the In Vitro Diagnostic Medical Device Regulation (IVDR), with the top ten companies having a market share exceeding 65%. As the world's second-largest medical market, China's in vitro diagnostic market is expected to reach 125.8 billion yuan in 2023. With a stable GDP growth rate of around 5% in the new normal of the economy, the industry is exhibiting countercyclical growth characteristics. It is worth noting that the export volume of diagnostic reagents exceeded 30 billion yuan for the first time, among which the contribution rate of countries along the "the Belt and Road" increased to 37%, marking a new stage in the global layout of the industry. The market transformation brought about by economic structural adjustment Driven by the development pattern of "dual circulation", the domestic in vitro diagnostic market presents three major structural changes: 1. Consumer upgrading drives an increase in the proportion of high-end products, with an annual increase of 25% in the installed capacity of chemiluminescence detection equipment. The number of single machine detection projects in tertiary hospitals has exceeded 150 2. The rapid rise of the county-level medical market has led to a 41% year-on-year increase in the purchase of POCT equipment by primary healthcare institutions in 2023 3. The innovation of service models is accelerating, and the revenue growth rate of third-party medical testing services has reached 34%, significantly higher than the sales growth rate of traditional products Of particular note is the surge in demand for products that combine cost-effectiveness and diagnostic accuracy among medical institutions in the context of healthcare payment reform (DRGs/DIP). In 2023, the daily average detection volume of a single fully automatic biochemical analyzer in China exceeded 2000 tests, which is three times higher than five years ago, confirming the trend of equipment upgrading driven by operational efficiency. The dual empowerment effect of policy environment The coordinated efforts of regulatory policies and industrial policies are reshaping the competitive landscape of the industry. After the implementation of the new version of the "Classification Catalogue of Medical Devices" in 2023, the average registration period for Class II IVD products will be shortened to 14 months, and the utilization rate of the special approval channel for innovative products will increase by 60%. The "14th Five Year Plan" for the development of the medical equipment industry clearly proposes five major technological directions for key development, including microfluidic chips and single-molecule detection. Under policy guidance, the R&D investment intensity in related fields has reached 12.8%. At the level of quality supervision, the frequency of flight inspections conducted by the National Medical Products Administration has increased by 45% year-on-year, and the failure rate of flight inspections has decreased from 17% in 2019 to 6% in 2023, significantly improving the standardization level of the industry. It is worth noting that the IVD reagent UDI (Unique Identification) full process traceability system launched in 2024 will drive the industry into a new stage of digital supervision. Resonance between Capital Market and Industrial Innovation Under the background of deepening the registration system reform, the IPO financing in the IVD field reached 21.8 billion yuan in 2023, setting a new historical high. The average R&D investment of the 15 IVD companies listed on the Science and Technology Innovation Board accounts for 19%, significantly higher than the industry average. The strong support of the capital market drives enterprises to accelerate their layout: 1. In the field of molecular diagnostics, the localization rate of digital PCR equipment has exceeded 40% 2. Mass spectrometry detection field: Domestic enterprises have obtained 25 clinical mass spectrometry reagent registration certificates 3. Smart Laboratory: LIS system penetration rate increases to 78%, AI assisted diagnostic module installation increases by 150% annually Under the dual drive of policies and capital, the industry is forming a virtuous cycle of "innovative research and development clinical validation industrialization". In 2023, the number of PCT patent applications in the IVD field in China will reach 1562, with a year-on-year increase of 28%, of which technological breakthroughs in subdivisions such as infectious diseases detection and early screening of tumors will be particularly significant. Hubei Xindesheng Material Technology, as a well-established enterprise in IVD core raw materials, helps domestic molecular diagnostic equipment shorten the technological gap with imported products. Through the dual wheel drive of "raw materials+algorithms", Xindesheng is providing the industry with a bottom-up technology solution that combines cost advantages and quality breakthroughs.  

Population structure changes give rise to rigid demand The elderly population aged 60 and above in China has exceeded 280 million, and the per capita medical expenditure of this group is 3.2 times that of young adults, directly promoting the expansion of the chronic disease testing market at a compound annual growth rate of 18%. In the field of diabetes management, the market scale of blood glucose monitoring products reached 9.5 billion yuan, and the market penetration rate of CGMS rapidly increased from 5% in 2020 to 17% in 2023. The adjustment of the birth policy brings structural opportunities. In 2023, the sales of prenatal screening reagents increased by 31% year-on-year, and the genetic disease testing projects for newborns have covered more than 200 diseases. It is worth noting that the tumor early screening market has shown explosive growth, with sales of 800 million yuan in the first year of the launch of multi cancer joint detection products based on NGS technology. Upgrading health consumption drives market segmentation The per capita healthcare expenditure of residents has increased to 8.7% of consumption expenditure, giving rise to three major consumption trends: 1. Precise testing demand: The number of users for personalized drug genetic testing services has exceeded 5 million 2. Convenience demand: the annual growth rate of the household self-test product market reached 45%, and the COVID-19 antigen test continued to increase after normalization 3. Preventive testing: The penetration rate of cancer early screening products in the 35-50 age group has increased to 12% The upgrading of consumption is also reflected in the improvement of testing quality requirements. Third level hospitals require a coverage rate of 92% for the traceability ability of testing items, and as a result, the market size of quality control products maintains an annual growth rate of over 20%. In terms of payment ability, the number of testing projects covered by commercial health insurance has increased from 87 in 2019 to 215 in 2023, significantly expanding the high-end testing market space. Structural opportunities brought by healthcare system reform After the deepening implementation of the hierarchical diagnosis and treatment system, the number of testing projects carried out in primary medical institutions will increase by 38% year-on-year in 2023, promoting the continuous expansion of the POCT equipment market. The construction of medical consortia has led to the rise of regional testing centers, with 70% of county-level medical consortia achieving mutual recognition of testing results, driving the sinking of high-throughput testing equipment into the market. The DRG payment reform has forced medical institutions to optimize their testing processes. By 2023, the average testing turnover time (TAT) of tertiary hospitals will be reduced to 2.1 hours, an increase of 40% in efficiency compared to before the reform. This transformation directly stimulates the demand for automated assembly lines, with an annual increase of 65% in the installed capacity of laboratory automation systems (LAS) in China, and the maximum number of connected modules in a single laboratory reaching 12. Innovation in the Mode of Third Party Inspection Services The market concentration of ICL (Independent Medical Laboratory) continues to increase, with the top three companies accounting for 68% of the market share. There are three major development trends in the industry in 2023: 1. The proportion of special testing services has increased to 35%, with tumor gene testing and rare disease diagnosis becoming growth engines 2. Digital service upgrade, 88% of ICLs achieve mobile report query and intelligent interpretation 3. Extension of the industrial chain, leading enterprises begin to lay out accompanying diagnostic centers and precision treatment alliances Breakthroughs have been made in the construction of regional testing centers, with an average daily testing volume of over 100000 items in 23 provincial-level regional testing centers. The economies of scale have reduced the cost of single testing by 28%. In the field of emergency detection, the establishment of a pathogen monitoring network in 78 cities has shortened the response time for detecting new infectious diseases to 48 hours. Deep integration of technological innovation and clinical needs The clinical demand-oriented research and development model has achieved significant results: In the field of severe illness, the detection time of early diagnostic indicators for sepsis is advanced to 4 hours after the onset of symptoms Chronic disease management: the dynamic monitoring system based on wearable devices increased the compliance rate of diabetes control by 25% Tumor diagnosis and treatment: MRD (minimal residual lesion) detection technology achieves a recurrence monitoring sensitivity of 0.01% The collaborative innovation mechanism between medical institutions and enterprises is gradually improving. In 2023, 27 "Medical Engineering Cross Union Laboratories" will be established to promote the clinical translation of 15 innovative testing technologies. In terms of standard construction, the latest 23 industry standards, including the "Expert Consensus on Clinical Application of Liquid Chromatography Mass Spectrometry," have paved the way for the application of new technologies. Hubei Xindesheng Material Technology has built a comprehensive solution covering the entire diagnostic process, focusing on core products such as blood collection tube additives, biological buffering agents, and chromogenic substrates. Assist medical institutions in addressing the challenges of DRG payment reform. By continuously providing cost-effective raw material products, enterprises are becoming a solid support for the development of inclusive healthcare.

In the chemical industry, anionic surfactants are an important class of compounds with wide applications. They not only have excellent wetting, dispersing, emulsifying, foaming, and washing properties, but also play a key role in fields such as medicine, pesticides, textiles, cosmetics, and food industry. As a multifunctional compound, the biological buffer CAPSO buffer (3- (cyclohexylamine) -2-hydroxy-1-propanesulfonic acid) exhibits unique advantages in the preparation of anionic surfactants due to its unique chemical structure and properties. Basic properties of CAPSO CAPSO is a white powdery substance with good water solubility. The molecular structure of CAPSO contains both hydrophilic sulfonate groups and highly active hydroxyl groups, which makes it easy for CAPSO to undergo reactions such as detachment and substitution, thus endowing it with diversity as a functional substance. The advantages of CAPSO in preparing anionic surfactants 1. Environmental friendliness: CAPSO, as a biological buffering agent, is usually prepared using environmentally friendly raw materials and has mild reaction conditions, reducing the emission of harmful substances. 2. Efficiency: The active hydroxyl and sulfonate groups of CAPSO endow it with excellent reactivity, enabling the reaction to be completed in a relatively short time and improving production efficiency. 3. Multifunctionality: By adjusting the structure and reaction conditions of CAPSO, anionic surfactants with different properties and applications can be prepared to meet various application needs. 4. Biocompatibility: CAPSO, as a biological buffering agent, usually produces anionic surfactants with good biocompatibility, which are suitable for fields such as medicine, cosmetics, and food industry. Application examples The anionic surfactants prepared by CAPSO have shown broad application prospects in multiple fields. For example, in the detergent industry, alkyl sulfonate surfactants prepared by CAPSO have excellent washing performance and biodegradability, becoming an important component of environmentally friendly detergents. In the pesticide industry, anionic surfactants prepared by CAPSO can serve as synergists for pesticides, improving their adhesion and permeability, thereby enhancing their insecticidal efficacy and utilization rate. In the cosmetics industry, anionic surfactants prepared by CAPSO can be used as emulsifiers, dispersants, and stabilizers for the preparation of various cosmetic formulations. Conclusion In summary, the biological buffer CAPSO has unique application advantages and broad application prospects in the preparation process of anionic surfactants. By fully utilizing the chemical structure and properties of CAPSO, anionic surfactants with excellent performance and environmental characteristics can be prepared to meet various industrial application needs. In the future, with the deepening of the concepts of green chemistry and sustainable development, the application of CAPSO in the preparation of anionic surfactants will be further expanded and deepened. Desheng Biochemical is a professional manufacturer of CAPSO, with a series of products such as biological buffering agents available for everyone to choose from, as well as blood collection tube additives, luminescent reagents, and new Trinder's reagent series products. We have been developing and producing for 20 years now, with rich experience, skilled team, and guaranteed product quality. We will never let customers take the wrong path or waste money. And as a manufacturer direct sales, Desheng has a complete pre-sales and after-sales service, even if there are problems with the goods, we can solve them for you as soon as possible. If you have such needs, please click on the official website or call for consultation!